A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients
Active, not recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/Phase 2
This study evaluates the tolerability, safety, pharmacokinetics and efficacy of SHR3680 in
patients with metastatic castration-resistant prostate cancer (mCPRC). All participants will
receive SHR3680.
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
Completed
Atridia Pty Ltd.
Phase 1
This is a multicenter, dose-escalation/expansion phase 1 trial to evaluate the safety,
tolerability and efficacy of SHR3680 with or without SHR3162 given orally to subjects with
metastatic castration-resistant prostate cancer (mCRPC).
A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer
Active, not recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in
the treatment of patients with hormone sensitive prostate cancer.
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
Terminated
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/Phase 2
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of
SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic
Castration Resistant Prostate Cancer.
This is a Phase Ib/II, open-label, umbrella study evaluating the efficacy and safety of
multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping
of patients' depends on FUSCC 500+ gene panel testing and IHC subtype staining.
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Active, not recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to
improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's
overall survival (OS) is superior to placebo.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
